Mayo Biotech Ovagen Raises €2M for Vaccine Development and Workforce Expansion
Tuesday, 29 October 2024, 07:02
Mayo Biotech Ovagen Secures Funding
Mayo Biotech Ovagen has successfully raised €2M in a recent investment round led by the WDC. This funding will enhance the company's development of world’s first germ-free eggs specifically for vaccine research.
Expansion Plans
- New hires: Ovagen plans to add 60 employees to its team.
- Focus on improving production and innovation in biotechnology.
The advancements in vaccine technology underscore the vital role of funding and workforce advancement in the field.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.